The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10–16 weeks of gestation
Article first published online: 12 DEC 2002
Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology
Ultrasound in Obstetrics & Gynecology
Volume 17, Issue 4, pages 295–300, April 2001
How to Cite
Antolín, E., Comas, C., Torrents, M., Muñoz, A., Figueras, F., Echevarría, M., Cararach, M. and Carrera, J. M. (2001), The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10–16 weeks of gestation. Ultrasound Obstet Gynecol, 17: 295–300. doi: 10.1046/j.1469-0705.2001.00395.x
- Issue published online: 12 DEC 2002
- Article first published online: 12 DEC 2002
- Manuscript Accepted: 8 FEB 2001
- Manuscript Revised: 8 NOV 2000
- Manuscript Received: 3 DEC 1999
- Cited By
- Ductus venosus;
- Chromosomal abnormalities;
- Doppler ultrasonography;
- Ultrasound screening
To evaluate the role of ductus venosus blood flow assessment at 10–16 weeks' gestation in screening for chromosomal abnormalities.
Ductus venosus blood flow was prospectively evaluated in 1371 consecutive pregnancies between 10 and 16 weeks of gestation. The pulsatility index for veins was calculated. All cases were screened for chromosomal defects combining maternal age and fetal nuchal translucency thickness.
A chromosomal abnormality was found in 20 cases. The overall detection rate, specificity, positive predictive value, negative predictive value and odds ratio for chromosomal abnormalities were 65%, 95.7%, 18.3%, 99.5% and 41 (95% CI 16–108), respectively, when using the 95th centile pulsatility index as a cut-off.
These preliminary results suggest that evaluation of the ductus venosus pulsatility index at 10–16 weeks' gestation is a useful second-line screening test for chromosomal defects. A combination of nuchal translucency measurement and ductus venosus assessment might increase specificity while maintaining an optimal detection rate for chromosomal abnormalities. Such a policy could identify 55% of all chromosomal abnormalities and about 69% of autosomal trisomies, reducing the need for invasive testing to less than 1%. Copyright © 2001 International Society of Ultrasound in Obstetrics and Gynecology